Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regenxbio (RGNX) EBIT Margin (2016 - 2025)

Regenxbio has reported EBIT Margin over the past 12 years, most recently at 189.99% for Q4 2025.

  • Quarterly results put EBIT Margin at 189.99% for Q4 2025, up 5216.0% from a year ago — trailing twelve months through Dec 2025 was 94.58% (up 18546.0% YoY), and the annual figure for FY2025 was 94.58%, up 18546.0%.
  • EBIT Margin for Q4 2025 was 189.99% at Regenxbio, down from 176.27% in the prior quarter.
  • Over the last five years, EBIT Margin for RGNX hit a ceiling of 78.66% in Q4 2021 and a floor of 408.8% in Q1 2024.
  • Median EBIT Margin over the past 5 years was 239.58% (2021), compared with a mean of 228.77%.
  • Biggest five-year swings in EBIT Margin: tumbled -26297bps in 2022 and later soared 42243bps in 2025.
  • Regenxbio's EBIT Margin stood at 78.66% in 2021, then tumbled by -334bps to 184.31% in 2022, then plummeted by -56bps to 287.68% in 2023, then rose by 16bps to 242.14% in 2024, then increased by 22bps to 189.99% in 2025.
  • The last three reported values for EBIT Margin were 189.99% (Q4 2025), 176.27% (Q3 2025), and 296.26% (Q2 2025) per Business Quant data.